Shanghai Reigncom Biotechnology, a Chinese medical device and services provider, has raised hundreds of millions of US dollars in series A funding. This financing is led by Matrix Partners China, followed by Sinovation Ventures and angel investor Wosheng Investment. Gelu Capital acts as the exclusive financial advisor. Reigncom Biotech will use the financing proceeds in talent recruitment, mass spectrometers for clinical use R&D and marketing.
